Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-CVOT: Tirzepatide vs Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes
2019-002735-28Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of tirzepatide in type 2 diabetes mellitus (T2DM) and cardiac morbidity (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to first occurrence of a component event of MACE-3. Started Jan 2020; status: active.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on 2019-002735-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002735-28.